Marc Abramowicz

Marc Abramowicz

Auto-generated profile, based on publicly available information

Marc Abramowicz

Human Genetics Unit, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles (ULB), Brussels, Belgium

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2010 in Nature
Verified
Journal Article
Open access
PDF file
SSStuart B. Smith
Stuart B. Smith
Hui-Qi QuHui-Qi Qu
Hui-Qi Qu
NTNadine Taleb
Nadine Taleb
NKNina Y. Kishimoto
Nina Y. Kishimoto
DSDavid W. Scheel
David W. Scheel
MGMichael S. German
Michael S. German
Insulin from the β-cells of the pancreatic islets of Langerhans controls energy homeostasis in vertebrates, and its deficiency causes diabetes mellitus. During embryonic development, the transcription factor neurogenin 3 (Neurog3) initiates the differentiation of the β-cells and other islet cell types from pancreatic endoderm, but the genetic program that subsequently completes this differentiation remains incompletely understood. Here we show that the transcription factor Rfx6 directs islet cell differentiation downstream of Neurog3. Mice lacking Rfx6 failed to generate any of the normal islet cell types except for pancreatic-polypeptide-producing cells. In human infants with a similar autosomal recessive syndrome of neonatal diabetes, genetic mapping and subsequent sequencing identified mutations in the human RFX6 gene. These studies demonstrate a unique position for Rfx6 in the hierarchy of factors that coordinate pancreatic islet development in both mice and humans. Rfx6 could prove useful in efforts to generate β-cells for patients with diabetes.

3 October 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ANAdeline K Nicholas
Adeline K Nicholas
MKMaryam Khurshid
Maryam Khurshid
JDJulie Désir
Julie Désir
OCOfelia Carvalho
Ofelia Carvalho
JCJames J Cox
James J Cox
GWGeoff Christopher Woods
Geoff Christopher Woods

29 August 2013 in Human Mutation
Verified
Journal Article
Closed access
PDF file
NRNicole Revencu
Nicole Revencu
LBLaurence M. Boon
Laurence M. Boon
AMAntonella Mendola
Antonella Mendola
MCMaria Rosa Cordisco
Maria Rosa Cordisco
JDJosée Dubois
Josée Dubois
Miikka VikkulaMiikka Vikkula
Miikka Vikkula
Capillary malformation–arteriovenous malformation (CM–AVM) is an autosomal‐dominant disorder, caused by heterozygous RASA1 mutations, and manifesting multifocal CMs and high risk for fast‐flow lesions. A limited number of patients have been reported, raising the question of the phenotypic borders. We identified new patients with a clinical diagnosis of CM–AVM, and patients with overlapping phenotypes. RASA1 was screened in 261 index patients with: CM–AVM (n = 100), common CM(s) (port‐wine stain; n = 100), Sturge–Weber syndrome (n = 37), or isolated AVM(s) (n = 24). Fifty‐eight distinct RASA1 mutations (43 novel) were identified in 68 index patients with CM–AVM and none in patients with other phenotypes. A novel clinical feature was identified: cutaneous zones of numerous small white pale halos with a central red spot. An additional question addressed in this study was the “second‐hit” hypothesis as a pathophysiological mechanism for CM–AVM. One tissue from a patient with a germline RASA1 mutation was available. The analysis of the tissue showed loss of the wild‐type RASA1 allele. In conclusion, mutations in RASA1 underscore the specific CM–AVM phenotype and the clinical diagnosis is based on identifying the characteristic CMs. The high incidence of fast‐flow lesions warrants careful clinical and radiologic examination, and regular follow‐up.

1 December 1990 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CMCarine Maenhaut
Carine Maenhaut
JSJacqueline Van Sande
Jacqueline Van Sande
FLFrédérick Libert
Frédérick Libert
MAMarc Abramowicz
Marc Abramowicz
MPMarc Parmentier
Marc Parmentier
SSSerge Schiffmann
Serge Schiffmann

1 October 2015 in Cell Reports
Verified
Journal Article
Open access
DFDebora Fumagalli
Debora Fumagalli
DGDavid Gacquer
David Gacquer
FRFrançoise Rothé
Françoise Rothé
ALAnne Lefort
Anne Lefort
FLFrederick Libert
Frederick Libert
VDVincent Detours
Vincent Detours
Little is known about how RNA editing operates in cancer. Transcriptome analysis of 68 normal and cancerous breast tissues revealed that the editing enzyme ADAR acts uniformly, on the same loci, across tissues. In controlled ADAR expression experiments, the editing frequency increased at all loci with ADAR expression levels according to the logistic model. Loci-specific "editabilities," i.e., propensities to be edited by ADAR, were quantifiable by fitting the logistic function to dose-response data. The editing frequency was increased in tumor cells in comparison to normal controls. Type I interferon response and ADAR DNA copy number together explained 53% of ADAR expression variance in breast cancers. ADAR silencing using small hairpin RNA lentivirus transduction in breast cancer cell lines led to less cell proliferation and more apoptosis. A-to-I editing is a pervasive, yet reproducible, source of variation that is globally controlled by 1q amplification and inflammation, both of which are highly prevalent among human cancers.

1 January 2001 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
HLH.-J. Lüdecke
H.-J. Lüdecke
JSJ. Schaper
J. Schaper
PMP. Meinecke
P. Meinecke
PMP. Momeni
P. Momeni
SGS. Groß
S. Groß
BHB. Horsthemke
B. Horsthemke